Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that the Company has demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. It uses a magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals.
äŒæ¥ã³ãŒãACONW
äŒç€ŸåAclarion Inc
äžå Žæ¥Apr 22, 2022
æé«çµå¶è²¬ä»»è
ãCEOãMr. Brent Ness
åŸæ¥å¡æ°- -
蚌åžçš®é¡Company Warrant
æ±ºç®ææ«- -
æ¬ç€Ÿæåšå°8181 Arista Place
éœåžBROOMFIELD
蚌åžååŒæNASDAQ Capital Market Consolidated
åœUnited States of America
éµäŸ¿çªå·80021
é»è©±çªå·18332752266
ãŠã§ããµã€ãhttps://aclarion.com/
äŒæ¥ã³ãŒãACONW
äžå Žæ¥Apr 22, 2022
æé«çµå¶è²¬ä»»è
ãCEOãMr. Brent Ness
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã